AKE:EURONEXT PARISArkema SA Analysis

Akebia Therapeutics (AKE) is trading well below its 20‑day, 50‑day and 200‑day moving averages, confirming a bearish price trend. RSI signals oversold conditions while the MACD shows a marginal bullish histogram, suggesting limited short‑term upside. Recent earnings disclosed a first‑quarter loss and a miss on EPS expectations, driving a sharp share‑price decline and heightened investor skepticism. Volume is decreasing, and the stock exhibits extremely high 30‑day volatility, reinforcing the near‑term risk profile. However, the discounted cash‑flow model values the company at more than three dollars, implying a substantial upside potential relative to the current sub‑one‑dollar price. The pipeline, especially the growth in Vafseo revenues and ongoing Phase 2 trials, offers a longer‑term growth narrative that could re‑anchor valuation if execution improves.